ASD-49

ASD-49 is a novel selenium-containing hybrid molecule derived from aspirin, specifically incorporating a selenocyanate moiety. Developed by researchers at the Penn State University College of Medicine, it was designed to enhance the anticancer properties of non-steroidal anti-inflammatory drugs (NSAIDs) by leveraging the redox-active and chemopreventive properties of selenium. In preclinical studies, ASD-49 demonstrated significant cytotoxicity against various cancer cell lines, including colon (HCT116) and pancreatic (MiaPaCa-2) cancer, with IC50 values in the low micromolar range (1.0 μM and 2.5 μM, respectively). Its mechanism of action involves the induction of apoptosis, characterized by caspase activation and subsequent PARP cleavage, showing markedly higher potency compared to parent aspirin.

Other names

selenium-aspirin hybridselenocyanate-aspirin hybrid